Takeaway

• The addition of toripalimab to the standard first-line therapy with gemcitabine-cisplatin improves progression-free survival (PFS) and objective response rate (ORR) in patients with recurrent/metastatic nasopharyngeal carcinoma (r/mNPC) compared with placebo.
• The combination could become the new standard of care in this setting.

Why this matters

• NPC represents a global...